Roundview Capital’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $413K | Sell |
2,707
-4
| -0.1% | -$613 | 0.03% | 277 |
|
|
2025
Q4 | $374K | Buy |
2,711
+66
| +2% | +$8.64K | 0.02% | 278 |
|
|
2025
Q3 | $339K | Hold |
2,645
| – | – | 0.02% | 290 |
|
|
2025
Q2 | $320K | Sell |
2,645
-13
| -0.5% | -$1.47K | 0.02% | 285 |
|
|
2025
Q1 | $296K | Sell |
2,658
-149
| -5% | -$15.9K | 0.02% | 282 |
|
|
2024
Q4 | $273K | Buy |
2,807
+149
| +6% | +$15.9K | 0.02% | 304 |
|
|
2024
Q3 | $306K | Hold |
2,658
| – | – | 0.02% | 301 |
|
|
2024
Q2 | $283K | Sell |
2,658
-36
| -1% | -$3.61K | 0.02% | 290 |
|
|
2024
Q1 | $261K | Sell |
2,694
-230
| -8% | -$23.6K | 0.02% | 295 |
|
|
2023
Q4 | $295K | Sell |
2,924
-35
| -1% | -$3.38K | 0.03% | 278 |
|
|
2023
Q3 | $301K | Hold |
2,959
| – | – | 0.03% | 273 |
|
|
2023
Q2 | $299K | Hold |
2,959
| – | – | 0.03% | 273 |
|
|
2023
Q1 | $272K | Sell |
2,959
-5,827
| -66% | -$509K | 0.03% | 286 |
|
|
2022
Q4 | $797K | Hold |
8,786
| – | – | 0.09% | 202 |
|
|
2022
Q3 | $668K | Buy |
8,786
+24
| +0.3% | +$1.99K | 0.08% | 200 |
|
|
2022
Q2 | $741K | Hold |
8,762
| – | – | 0.09% | 196 |
|
|
2022
Q1 | $769K | Sell |
8,762
-77
| -0.9% | -$6.67K | 0.08% | 202 |
|
|
2021
Q4 | $773K | Sell |
8,839
-897
| -9% | -$74.5K | 0.08% | 214 |
|
|
2021
Q3 | $796K | Sell |
9,736
-143
| -1% | -$12.9K | 0.09% | 204 |
|
|
2021
Q2 | $901K | Hold |
9,879
| – | – | 0.1% | 194 |
|
|
2021
Q1 | $844K | Buy |
9,879
+152
| +2% | +$13.6K | 0.11% | 184 |
|
|
2020
Q4 | $919K | Buy |
9,727
+40
| +0.4% | +$3.5K | 0.13% | 158 |
|
|
2020
Q3 | $842K | Sell |
9,687
-8
| -0.1% | -$693 | 0.13% | 145 |
|
|
2020
Q2 | $847K | Sell |
9,695
-202
| -2% | -$17.4K | 0.14% | 147 |
|
|
2020
Q1 | $816K | Buy |
9,897
+807
| +9% | +$72K | 0.17% | 145 |
|
|
2019
Q4 | $861K | Buy |
9,090
+58
| +0.6% | +$5.2K | 0.16% | 152 |
|
|
2019
Q3 | $785K | Buy |
9,032
+145
| +2% | +$13K | 0.17% | 151 |
|
|
2019
Q2 | $811K | Sell |
8,887
-688
| -7% | -$58.2K | 0.18% | 138 |
|
|
2019
Q1 | $825K | Buy |
9,575
+502
| +6% | +$40.3K | 0.2% | 130 |
|
|
2018
Q4 | $698K | Buy |
9,073
+1,467
| +19% | +$114K | 0.2% | 127 |
|
|
2018
Q3 | $587K | Buy |
7,606
+279
| +4% | +$20.6K | 0.14% | 155 |
|
|
2018
Q2 | $496K | Buy |
7,327
+754
| +11% | +$52K | 0.13% | 164 |
|
|
2018
Q1 | $476K | Sell |
6,573
-2,640
| -29% | -$201K | 0.13% | 154 |
|
|
2017
Q4 | $693K | Buy |
9,213
+1,139
| +14% | +$85.9K | 0.18% | 135 |
|
|
2017
Q3 | $621K | Sell |
8,074
-67
| -0.8% | -$5.06K | 0.18% | 139 |
|
|
2017
Q2 | $609K | Hold |
8,141
| – | – | 0.18% | 143 |
|
|
2017
Q1 | $542K | Hold |
8,141
| – | – | 0.17% | 142 |
|
|
2016
Q4 | $531K | Buy |
+8,141
| New | +$528K | 0.17% | 142 |
|
|
2014
Q4 | – | Sell |
-36,491
| Closed | -$3.08M | – | 150 |
|
|
2014
Q3 | $3.08M | Sell |
36,491
-335
| -0.9% | -$27.1K | 1.38% | 20 |
|
|
2014
Q2 | $2.99M | Sell |
36,826
-1,701
| -4% | -$134K | 1.21% | 21 |
|
|
2014
Q1 | $2.94M | Sell |
38,527
-111
| -0.3% | -$8.09K | 1.43% | 16 |
|
|
2013
Q4 | $2.78M | Sell |
38,638
-1,116
| -3% | -$77.6K | 1.28% | 19 |
|
|
2013
Q3 | $2.73M | Buy |
39,754
+307
| +0.8% | +$20.3K | 1.42% | 17 |
|
|
2013
Q2 | $2.5M | Buy |
+39,447
| New | +$2.57M | 1.57% | 14 |
|
Other funds holding NVS
Roundview Capital's NVS Position: Q1 2026 in Review
Roundview Capital reduced its Novartis (NVS) stake by 0.15% in Q1 2026, selling an estimated $613 and leaving 2,707 shares worth $413K. The position accounts for 0.03% of the portfolio, ranked #277.
Roundview Capital first reported a position in NVS in Q2 2013 and has held it in 44 quarters since. The position peaked at $3.08M in Q3 2014. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Roundview Capital held 2,707 shares of Novartis worth $413K as of Q1 2026.
- Roundview Capital sold 4 Novartis shares in Q1 2026, an estimated $613.
- Novartis made up 0.03% of Roundview Capital's portfolio in Q1 2026, its #277 holding.
- Roundview Capital first reported a position in Novartis in Q2 2013 and has held it in 44 quarters since.
- Roundview Capital's Novartis position peaked at $3.08M in Q3 2014.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Roundview Capital's 13F filing for Q1 2026, filed 8 May 2026.